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Abstract: The classic single-arm oncology phase II trial designs for
evaluating an experimental regimen/agent are limited by multiple
sources of bias arising from the inability to separate trial effects
(such as patient selection, trial eligibility, imaging techniques and
assessment schedule, and treatment locations) from treatment effect
on clinical outcomes. Changes in patient population based on bio-
logic subsetting, newer imaging technologies, the use of alternative
end points, constrained resources, and the multitude of promising
therapies for a given disease make randomized phase II designs,
with a concurrent control arm where necessary, attractive. In this
brief report, we discuss the salient features of the randomized
designs for phase II trials, which when properly applied under the
constraints of their underlying inference framework can assure
optimal use of limited phase III financial and patient resources.
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Phase II clinical trials are designed to identify promisingexperimental therapies that can then be tested further in a
definitive phase III trial. With the recent explosion of molec-
ularly targeted agents in oncology, frequently resulting in
multiple agents aiming at the same target, coupled with the
growth in combination therapies for cancer treatment, there is
a definite need to evaluate the efficacy of multiple regimens
quickly and concurrently. The spiraling costs of phase III
trials demand that the failure rate of such trials be reduced.
Changes in patient population based on biologic subsetting
and evolution in imaging technologies make comparison
against historical controls inaccurate. Moreover, with new
biologic agents, end points such as tumor response are no
longer useful because many of these agents are cytostatic; the
subsequent appropriate use of alternative end points such as
progression-free survival in a phase II setting imply a greater
need for concurrent control. The classic single-arm phase II
trial designs for evaluating each experimental regimen/agent
individually are limited by outcome-trial effect confounding
arising from the inability to separate trial effects (such as
patient selection, trial eligibility, imaging techniques and
assessment schedule, and treatment locations) from treatment
effect on clinical outcomes. Designs with randomization
(using stratification or dynamic allocation where necessary)
to experimental regimens/agents, using a concurrent control
arm when necessary, offer an attractive proposition by assur-
ing better patient comparability and reducing outcome-trial
effect confounding.1–4 Moreover, randomized phase II de-
signs greatly enhance the potential for biomarker discovery,
which is an important first step toward the aim of personal-
ized medicine.
TYPES OF RANDOMIZED PHASE II DESIGNS
The design of a clinical trial is largely driven by three
statistical parameters: (1) , the type I error or probability of
a false-positive result, (2) , the type II error or probability of
a false-negative result, and (3) , the targeted difference or
targeted effect size. The sample size is determined to detect 
with a significance level of  and power of (1  )  100%.
The randomized phase II designs are differentiated by the
choice of the values for these statistical parameters, which is
dictated by the inference framework of the design.
Randomized phase II designs fall into one of the fol-
lowing three categories: (1) randomization to parallel non-
comparative single-arm experimental regimens each with
independent decision rule; (2) randomized selection (or pick
the winner) designs for selecting the most promising exper-
imental regimen among several similar experimental regi-
mens; and (3) randomized screening design for comparing an
experimental regimen to standard of care.3–7 We review the
salient features of each of these designs below.
Randomization to Parallel Noncomparative
Regimens
The first class of randomized designs includes random-
ization to two or more experimental treatment arms in which
the randomization is primarily for the purpose of reducing
various types of bias, including patient selection bias and
controlling for known or unknown baseline imbalances
across the arms. Each individual treatment arm within the
randomized phase II design is structured as an independent
phase II study with determination of “promising activity”
based on a comparison against historical control with appro-
priate thresholds for  (typically 0.1) and  (typically 0.1).
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The arms have independent decision rules including rules for
early termination for lack of efficacy. Such a design would be
useful in the concurrent evaluation of two or more experi-
mental regimes, with no direct comparison, such that each
regimen that meets the success criteria has the potential to be
tested further in a larger trial.
Although this is not a common design in most disease
settings, they are nevertheless attractive in early phase II
situations where there is a reliable early end point to demon-
strate success (such as tumor response) and that success on
that end point is directly attributable to the experimental
regimen in question (i.e., a single-agent trial). Success in such
a trial for the most part still dictates the need for a more
thorough evaluation of those regimens that show promise in
a phase IIb setting, with a direct comparison of safety and
efficacy outcomes between the randomized arms.
Randomized Selection Designs
The second class of randomized phase II designs was
first introduced by Simon et al.5 with the aim of choosing the
most promising experimental regimen from among similar
ones using a ranking and selection approach. The experimen-
tal regimen(s) selected as the most promising is then com-
pared with the standard of care in a subsequent larger phase
III trial. Scenarios in which such a design would be useful
include comparing different modes of drug administration or
dosing schedules or comparing different combination regi-
mens, all of which have a new experimental agent added to a
common core regimen.
Selection designs are designed to make a prioritization
between promising “experimental” regimens when there is no
a priori data to prefer one regimen over the other. In this
design, patients are randomized to two or more “competing”
regimens/agents. The final results are then ranked, and the
arm with the best observed outcome is selected for further
study. The sample size requirements for this design are based
on providing a high probability of choosing the best arm as
long as the expected outcome in that arm exceeds any other
arm by a clinically meaningful margin (e.g., at least 15%).
This design does not provide answers concerning the relative
merits of similar regimens because it does not test the null
hypothesis of equality. This design approach was used by
Lustberg et al.8 to make a selection between two doses of
Mitomycin C followed by irinotecan in patients with ad-
vanced esophageal and gastroesophageal junction adenocar-
cinomas. The trial used a two-stage Simon design with
individual decision rules for efficacy for each experimental
arm with  and  of 0.1. The final results from the two arms
were ranked to make a recommendation that the low-dose
arm was both well tolerated and efficacious.
The selection of an experimental treatment in a screen-
ing design can be based solely on the primary end point or
can include other factors when the observed difference in the
primary outcome is deemed “small.”5–7 This is a flexible
selection design in which other factors such as safety profile,
cost, convenience, or quality of life in addition to the primary
efficacy measure are taken into consideration in making the
selection, much similar to clinical practice.6,9
Randomized Screening Designs
The third class of designs is the randomized screening
designs for performing a nondefinitive comparison of one or
more experimental regimes against the standard of care treat-
ment in a phase II setting. Such an approach was used in the
evaluation of two doses of bevacizumab combined with
carboplatin and paclitaxel (two experimental arms) versus
carboplatin and paclitaxel alone (concurrent control) in pre-
viously untreated patients with non-small cell lung cancer.10
The promising results from this randomized phase II trial for
the high-dose bevacizumab arm led to the pivotal phase III
trial that established the efficacy of bevacizumab plus carbo-
platin and paclitaxel in chemotherapy-naive non-small cell
lung cancer patients.11
Rubinstein et al.3 formally introduced the paradigm of
conducting preliminary and nondefinitive comparisons of
experimental regimens to standard of care by carefully se-
lecting the statistical parameters of , , and  such that there
is a high chance for identifying nonpromising regimens and
taking forward promising regimens for further testing. These
designs should not be viewed as a replacement for a definitive
phase III trial but rather as a tool to help prioritize experi-
mental regimens using an intermediate end point such as
tumor response or progression-free survival for a subsequent
more definitive evaluation.
The choice of the three statistical parameters in this
design is critical so the sample size is reasonable (typically
around 100 patients), and the results are meaningful. Specif-
ically, an overly large false-positive rate ( 0.20) has the
risk of increasing the likelihood of negative phase III trials; a
high value of  (0.20), the false-negative rate, has the risk
of terminating further testing of a potentially promising
regimen, and a high value of the targeted difference,  has the
risk of rejecting a potentially clinically beneficial regimen.
Rubinstein et al.3 recommend choosing 0.20 for both  and 
in a screening setting and a target difference of 20% (or
hazard ratio of 1.5). Rubinstein et al.3 provide a detailed
discussion of the possible choice of values for , , and  for
a screening design and its impact on the sample size and trial
results interpretation.
SUMMARY
Randomized phase II designs are gaining considerable
momentum in the current era of constrained resources cou-
pled with the multitude of promising therapies for a given
disease. The wealth of opportunities in cancer drug develop-
ment mandates intelligent clinical trial design. Randomized
phase II designs, when properly applied under the constraints
of their underlying inference framework, can assure optimal
use of limited phase III financial and patient resources.
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